Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

  • End date
    Feb 10, 2025
  • participants needed
  • sponsor
    Gilead Sciences
Updated on 27 October 2021
high risk myelodysplastic syndrome


The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

Condition Bone marrow disorder, Preleukemia, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), myelodysplastic syndromes, myelodysplastic syndrome (mds)
Treatment Placebo, Azacitidine, Magrolimab
Clinical Study IdentifierNCT04313881
SponsorGilead Sciences
Last Modified on27 October 2021


Yes No Not Sure

Inclusion Criteria

Previously untreated individuals with intermediate to very high risk Myelodysplastic Syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R)
Adequate performance status and hematological, liver, and kidney function

Exclusion Criteria

Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor
Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRP)-targeting agents
Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R
Contraindications to azacitidine
Clinical suspicion of active central nervous system (CNS) involvement by MDS
Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history
Pregnancy or active breastfeeding
Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note